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AbstrAct
Thrombotic microangiopathies (TMAs) 
are pathological conditions characterized 
by generalized microvascular occlusion by 
platelet thrombi, thrombocytopenia, and 
microangiopathic hemolytic anemia. Two 
typical phenotypes of TMAs are hemolyt-
ic-uremic syndrome (HUS) and thrombotic 
thrombocytopenic purpura (TTP). Other 
disorders occasionally present with simi-
lar manifestations. Depending on whether 
renal or brain lesions prevail, two patho-
logically indistinguishable but somehow 
clinically different disorders have been de-
scribed: HUS and TTP. Injury to the en-
dothelial cell is the central and likely incit-
ing factor in the sequence of events leading 
to TMA. Loss of physiological thrombore-
sistance, leukocyte adhesion to damaged 
endothelium, complement consumption, 
abnormal von Willebrand factor release 
and fragmentation, and increased vascular 
shear stress may then sustain and amplify 
the microangiopathic process. Intrinsic 
abnormalities of the complement system 
and of the von Willebrand factor pathway 
may account for a genetic predisposition 
to the disease that may play a paramount 
role in particular in familial and recurrent 
forms. In the case of diarrhea-associated 
HUS (D+HUS), renal endothelial damage 
is mediated (at least in large part) by the 
bacterial agent Shigatoxin (Stx), which is 
actually a family of toxins elaborated by 
certain strains of Escherichia coli and Shi-
gella dysenteriae. Outcome is usually good 
in childhood, Shiga toxin-associated HUS, 
whereas renal and neurological seque-
lae are more frequently reported in adult, 
atypical, and familial forms of HUS and 
in TTP. Recent studies have demonstrated 
that deficiency in the von Willebrand fac-
tor cleaving protease ADAMTS13, due to 
deficiency of ADAMTS13 can be genetic 
or more common, acquired, resulting from 
autoimmune production of inhibitory 
anti-ADAMTS13 antibodies, that causes 
TTP. During the last decade, atypical HUS 
(aHUS) has been demonstrated to be a dis-
order of the complement alternative path-
way dysregulation, as there is a growing 
list of mutations and polymorphisms in 
the genes encoding the complement regula-
tory proteins that alone or in combination 
may lead to aHUS. Approximately 60% 
of aHUS patients have so-called ‘loss-of-
function’ mutations in the genes encod-
ing the complement regulatory proteins, 
which normally protect host cells from 
complement activation: complement fac-
tor H (CFH), factor I (CFI) and membrane 
cofactor protein (MCP or CD46), or have 
‘gain-of-function’ mutations in the genes 
encoding the complement factor B or C3. 
In addition, approximately 10% of aHUS 
patients have a functional CFH deficiency 
due to anti-CFH antibodies. Although 
TMAs are highly heterogeneous pathologi-
cal conditions, one-third of TMA patients 
have severe deficiency of ADAMTS13. 
Platelet transfusions are contraindicated. 
Plasma infusion or exchange (PE) is the 
only treatment of proven efficacy. 
Keywords: thrombotic microangiopathies, 
thrombotic thrombocytopenic purpura, 
hemolytic-uremic syndrome, kidney failure, 
von Willebrand factor.
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IntroductIon
Thrombotic microangiopathies (TMAs) are patholo-
gical conditions characterized by the presence of mi-
croangiopathic hemolytic anemia (due to shear stress 
in the microcirculation), generalized microvascular 
occlusion caused by platelet-rich thrombi (renal in-
volvement is common), and thrombocytopenia (plate-
let consumption).1 The two classical phenotypic ma-
nifestations of TMAs are thrombotic thrombocytope-
nic purpura (TTP) and hemolytic-uremic syndrome 
(HUS), serious conditions that put the patient’s life 
at risk. Hemolytic-uremic syndrome is characterized 
by three already cited clinical signs (classical “triad”), 
while TTP is characterized by a set of five manifesta-
tions: the “triad” associated with fever and neurolo-
gical signs. However, the two diseases cannot be clini-
cally distinguished. Those TMAs should be differen-
tiated from disseminated intravascular coagulation 
(DIC) and from consumptive thrombo-hemorrhagic 
disorders.2 In fact, the spectrum of clinical manifes-
tations of such disorders is very similar, the neuro-
logical abnormalities being commonly considered a 
characteristic of TTP, while acute kidney failure is a 
characteristic of HUS. Patients with those syndromes 
can have both, or none, abnormalities. This distinc-
tion has been valued to a certain extent because of the 
suggestion that treatment with plasma exchange (PE) 
would be appropriate to TTP, but not to HUS. Even 
considering that both are significantly clinically and 
histologically related, most recent investigations have 
shown that TTP and HUS have independent and non-
related outcomes. Currently, investigations related to 
TTP have focused on the regulation of the blood co-
agulation protein, the von Willebrand factor (vWF), 
while studies on HUS have focused on understanding 
the mechanisms of renal endothelial injury.
It is worth emphasizing that the PE treatment is 
the combination of plasmapheresis (which can remo-
ve unusually large von Willebrand factor multimers 
and autoantibodies against ADAMTS13) and infu-
sion of frozen fresh or cryosupernatant plasma (con-
taining additional metalloprotease).3,20
diagnostic criteria for tMas (ttp and HUs)
According to previous studies,2,4,5 TMAs have been de-
fined as having all the following alterations: (1) micro-
angiopathic hemolytic anemia (hemoglobin ≤ 12 g/dL), 
negative Coombs test, undetectable serum haptoglobin 
(< 10 mg/dL), more than two fragmented red blood 
cells (schizocytes) in a 100-x microscopic field (Figure 
1), and an increase in lactic dehydrogenase (LDH) 
above the institutional baseline; (2) thrombocytopenia 
(platelet count ≤ 100x109/L); and (3) organic dysfunc-
tion (renal and neurological involvement) of variable 
intensity with no signs of DIC.6
The differential diagnosis between HUS and TTP 
based on routine laboratory findings is usually very 
difficult.7
Approximately 90% of children with HUS have 
diarrhea [HUS associated with diarrhea (D+ HUS)] as 
a prodrome, usually with blood, caused by Shiga toxin 
(Stx), typically produced by Escherichia coli of the se-
rotype O157:H7.8 With support therapy, its mortality 
is 3%,9 and, thus, treatment with PE is rarely necessa-
ry. Because that procedure is not used in children with 
HUS, the same diagnosis in adults can indicate that PE 
treatment is not necessary. Therefore, some authors 
avoid using the term HUS for adults, even in the pre-
sence of kidney failure. It is worth emphasizing that 
acute kidney failure manifests in 55% to 70% of the 
cases;10-12 however, kidney function recovers in most 
cases (more than 70% in several case series).12-15
Leukocytosis can be extreme, in the form of a leu-
kemoid reaction, being a positive predictor of acute 
mortality and residual nephropathy.16-19 Children wi-
th diarrhea (D+ HUS) present a significantly higher 
leukocyte count than children with atypical HUS (D- 
HUS). This finding suggests that the intestinal disorder 
is an important factor implicated in the generation of 
leukocytosis.17 In the Osaka outbreak in 1996, leu-
kocyte count and C reactive protein (CRP) levels were 
higher in the group of children with diarrhea who de-
veloped HUS, when compared with infected children 
without that complication.18
Atypical HUS involves a heterogeneous group of 
patients not infected by the Stx-producing bacterium 
(5% of the HUS cases), which should be excluded as a 
cause of the disease. Atypical HUS can be sporadic or 
familial (that is, more than one family member affec-
ted by the disorder, once exposure to Stx-producing E. 
coli is excluded). The forms of D- HUS have a poor 
prognosis. More than 50% progress to chronic kid-
ney failure or irreversible cerebral damage, and 25% 
evolve to death during the acute phase of the disease.16 
Recently, genetic studies have documented that the fa-
milial form is associated with genetic abnormalities of 
the complement regulatory protein, and there is evi-
dence that similar genetic alterations can also predis-
pose to sporadic cases of D- HUS.21
Unlike TTP, HUS is rarely induced by genetic mu-
tations of complement regulation factors (factors B, 
H, and I, and CD46) and by auto-antibodies against 
factor H.21
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Figure 1. Peripheral blood smear of a patient with TTP. 
In the era preceding its effective treatment, TTP 
was defined by the following “pentad” of clinical 
manifestations: thrombocytopenia; microangiopathic 
hemolytic anemia; neurological abnormalities; kidney 
failure; and sudden fever.19 Efficacy of the treatment 
with PE requires immediate diagnosis and a reduction 
in the number of clinical criteria necessary for diag-
nosing the disease. The diagnostic criteria that have 
been used more recently include only thrombocyto-
penia and microangiopathic hemolytic anemia, with 
no apparent alternative etiology.20 The use of fewer 
criteria is supported by the clinical findings at pre-
sentation of patients whose diagnosis of TTP had be-
en confirmed by the presence of severe deficiency of 
ADMTS13: neurological and renal abnormalities we-
re uncommon, fever was rare, and no patient had the 
complete “pentad” of clinical manifestations.22 The 
feasibility of effective treatment and the reduction in 
number of the diagnostic criteria have resulted in an 
eight- to ten-fold increase in the number of patients 
treated with PE in cases of TTP.23,24 Because the diag-
nosis of TTP requires that treatment to be considered, 
and because almost all adults who do not meet the 
diagnostic criteria for PTT can benefit from PE, some 
authors use the term TTP for almost all adults.
It is worth noting that, although a certain degree 
of kidney impairment with proteinuria and/or hema-
turia is common, arterial hypertension and acute kid-
ney failure requiring dialysis are rare in TTP.25
The distinction between TTP and HUS26 is extre-
mely important, because of the cases of atypical HUS, 
since D+ HUS affects mainly children, who typically 
have diarrhea before the episode of kidney failu-
re.8,27 It is worth emphasizing the recent evidence that 
neither the deficiency of ADAMTS13, nor the defi-
ciency of complement regulators are sufficient for the 
development of TTP or atypical HUS, respectively.25,27
acUte inflaMMation in tHe patHogenesis of HUs
Initially described in 1925 as a syndrome comprising 
kidney failure, hemolytic anemia, and thrombocyto-
penia, HUS is usually considered a kidney disease 
with systemic complications.1 While in TTP, the fo-
cus is on von Willebrand factor and ADAMTS13, in 
HUS, the focus is on the mechanism of renal endothe-
lium injury mediated by Stx (at least, mostly), a fami-
ly of toxins produced by certain strains of Escherichia 
coli and Shigella dysenteriae.29,28
Unlike TTP, patients with D+ HUS have plenty of 
evidence of an acute inflammatory response, whose 
magnitude predicts clinical outcome. There is eviden-
ce that inflammatory cells and their byproducts play 
a major role in: (1) loss of the intestinal barrier func-
tion, promoting the movement of endotoxin and Stx 
into the circulation; (2) delivery of Stx to target or-
gans; (3) sensitization of target organs to Stx by incre-
asing the intracellular glycolipid receptor expression; 
and (4) direct injury of target organ endothelium.29
The gastrointestinal disorder in patients with Stx-
producing E. coli varies from an aqueous diarrhea 
to a severe form of hemorrhagic colitis. Colonic in-
flammation could play a role in the local intestinal 
microangiopathy, in the Stx transportation from the 
intestinal lumen through lamina propria into the cir-
culation, and in the generation of severe systemic in-
flammatory response.29,30 Recent evidence shows that 
Stx induces marked chemotactic response of human 
intestinal epithelial cells.31 By using a colonic epithe-
lial cell line, Stx led to superinduction of interleukin-8 
(IL-8) with increase in both IL-8 protein and mRNA, 
despite the known inhibitory effects of Stx on protein 
elongation. Secretion of IL-8 into the lamina propria 
might create a chemokine gradient sufficient to recruit 
polymorphonuclear leukocytes (PMNs). Both IL-8 
and tumoral necrosis factor alpha (TNF-alpha) are 
very elevated in stools of patients infected with Stx-
producing S. flexneri.32 Several potential consequen-
ces of the inflammatory response in lamina propria 
exist. Transepithelial migration of PMNs can lead to 
transient loss of colonic barrier function and cause 
the passage of luminal contents into circulation.32-34 A 
recent study has shown the movement of PMNs from 
the basolateral membrane to the apical side of intes-
tinal epithelial cells and the increase in translocation 
of both Stx1 and Stx2 in the opposite direction.34 Loss 
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of barrier function could contribute to direct entry of 
Stx into the circulation, and endotoxemia could pro-
mote a systemic cytokine response. Increasing eviden-
ce, both in vitro and in vivo, suggests that Stx binds 
to PMNs, which is the trigger for their activation, and 
promotes adherence of PMNs to the target endothe-
lium. Recently, Te Loo et al.35 have found that Stx 
binds to PMNs (not via Gb3) and that these cells are 
direct carriers of the toxin from the intestine to target 
organs.36 Shiga toxin circulates in the body, but can be 
preferentially located in the kidney, as a result from 
the high concentration of its receptor, globotriaosyl-
ceramide (Gb3), in the endothelium.
The D+ HUS (Table 1) is caused by Stx1 and Stx2, 
a component of the subunit A of 33 kDa and five su-
bunits B of 7 kDa each, produced by Escherichia coli 
O157: H7.37 In the circulation, it binds to the Gb3 
receptor, which is widely expressed on glomerular en-
dothelial cells. After receptor-mediated endocytosis, 
the subunit A of Stx is internalized and activated, le-
ading to the depuration of specific adenosines in 28S 
ribosomal RNA, resulting in irreversible inhibition 
of protein elongation 38 and apoptosis of endothelial 
cells. This releases significant levels of Willebrand 
factor multimers (UL-VWFMS) into the circulation, 
resulting in platelet thrombi in the microcirculation. 
Glomerular endothelial cells and renal tubular epi-
thelial cells express the Gb3 receptor, contributing to 
the development of kidney failure in infected patients. 
Thus, E. coli O157:H7 associated with TMAs seems 
to be induced independently from the plasma levels 
of ADAMTS13:AC7 (normal activity of the vWF-cle-
aving protease), and efficacy of the treatment with PE 
is much less evident in such case.
By definition, the kidney is the target organ in 
HUS caused by Stx-producing E. coli. That vulnerabi-
lity is mostly due to the high density of Gb3 receptors 
in renal tubular epithelial and microvascular endo-
thelial cells.39 In fact, renal tubular epithelial cells are 
maybe the major source of Gb3, in a quantity equal 
to or possibly greater than that of Vero cells. The 
pending question is how much of that vulnerability 
is due to the cytotoxic environment. The studies by 
Hughes et al.40 and King et al.43 have shown that those 
cells are extremely sensitive to the ribotoxic effects of 
Stx. Those studies have increased the possibility that 
acute tubular necrosis plays a role in kidney failure. 
Human glomerular microvascular endothelial cells 
express less Gb3 and are less sensitive to the ribotoxic 
effects of Stx. Even if the subsequent events are less 
well known, it is clear that the thrombotic state in-
duced by Stx in HUS involves more than direct toxic 
effect. Pretreatment of the glomerular microvascular 
endothelial cells with TNF-alpha substantially increa-
sed the density of the receptors and their sensitivity to 
Stx.41 Those data suggest that inflammatory cytokines 
contribute to glomerular injury, because of an incre-
ase in Gb3 expression on glomerular microvascular 
endothelial cells, thus increasing the sensitivity of tho-
se cells to the ribotoxic effects of Stx and their vulne-
rability to undergo apoptosis. If the finding that Stx 
increases the expression of adhesion molecules is true 
for glomerular microvascular endothelial cells, such 
mechanism could serve as an accelerator of the glo-
merular injury due to an increase in Stx delivery.
Approximately 50% of the patients with atypical 
HUS (Table 2) carry a heterogeneous mutation in one 
of the four genes that encode the complement factors 
H (CFH), I (CFI), B (CFB), membrane cofactor pro-
tein (MCP) or CD46.45-43 Those proteins control the 
complement activation on cell surface and limit cell 
injury mediated by complement in the host tissue. 
However, because of only partially known reasons, 
the glomerular endothelium is especially sensitive to 
loss of complement regulation, and the microvascular 
damage in atypical HUS is mainly limited to the renal 
circulation.
Since 1974, reduced serum levels of complement 
component C3 and normal serum levels of C4 have 
been shown in patients with atypical HUS (Table 
2).44-47 Patients with HUS and low levels of C3 ha-
ve high activated complement (C) component levels, 
including C3b, C3c, and C3d. Granular deposits of 
C3 in glomeruli and arterioles during acute disease 
are consistent with complement activation and local 
C3 consumption.48 Positive staining for C9 in glome-
ruli and small arteries with intimal proliferation and 
thrombosis indicates activation through the final lytic 
pathway (membrane attack complex C5b-9).
It is worth noting that the complement system con-
sists of several plasma proteins and membrane-bound 
proteins that protect against the invasion of microor-
ganisms.47 There are three activation pathways (clas-
sical, lectin, and alternate), which produce proteases 
denominated C3 and C5 convertases, which cleave 
C3 and C5, respectively, and bind to the membrane 
attack complex. Hydrolysis of C3 in the plasma ini-
tiates the alternate pathway, leading to C3b deposi-
tion on almost all surfaces exposed to plasma. 47 In 
host cells, complement activation is controlled by 
both receptors, fluid-phase and membrane-anchored 
receptors, favoring C3b cleavage to inactive C3b 
(iC3d) by CFI (cofactor activity) and dissociating the 
multicomponents of C3 and C5-convertases (decay 
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Disease Causes Treatment
D+ HUS Stx-producing Escherichia coli Support
  Shigella dysenteriae type 1 Support and antibiotics
Non-Stx HUS (sporadic) Bacterium (Streptococcus pneumoniae) Antibiotics and plasma
  Virus (HIV) Plasma
  Drugs (antineoplastic, antiplatelet, 
immunosuppressive drugs) Drug interruption and plasma
  Pregnancy Delivery, plasma
  Post-partum Plasma
  Systemic diseases  
  Lupus Steroids and plasma
  Scleroderma Blood pressure control 
  Antiphospholipid syndrome Oral anticoagulant agents
  Idiopathic Plasma
  Genetic (CFH, MCP, CFI) Plasma
Familial Genetic (CFH, MCP, CFI), plasma Plasma
Table 1 classification and treatMent of tHe different forMs of HUs
accelerating activity). Without normal regulation, 
C3b deposits increase more than 20 times47 through 
the amplification loop and activate the complement 
cascade, which remains as such until the complement 
components are consumed. Injured cells that have no 
membrane-bound regulators or that cannot bind to 
soluble regulators are attacked by the complement. 
On the bacterial surface, C3b binds to specific re-
ceptors in neutrophils and macrophages, resulting in 
phagocytosis of the complement-labeled bacterium. 
Complement component C3b also participates in the 
formation of C5-convertase and initiates the attack 
complex that causes cell lysis. That thin regulation is 
based on a certain number of membrane regulators 
(CR1, DAF, MCP, and Cd59) and fluid-phase regula-
tors (Factor H) that protect the host cells.
This results in the formation of the membrane at-
tack complex and recruitment of inflammatory cells, 
events that cause injury and retraction of endothelial 
cells, platelet adhesion and aggregation, an increase in 
Gene Major 
effect
Principal 
efeito
Frequency 
(%)
Short-term response 
with plasma therapy 
Long-term 
evolution
Outcome 
of kidney 
transplant
CFH Factor H Does not 
bind to 
endothelium
20-30 Remission rate: 60% 
(dose- and time-
dependent)
Death rate or 
CKF: 70%-80%
Recurrence rate: 
80%-90%
CFHR1/3 HR1/R3 
factor 
Antibody anti-
CFH
6 Remission rate: 
70%-80% (PE and 
immunosuppressive 
agents)
CKF rate: 
30%-40%
Recurrence rate: 
20%
MCP MCP Lack of 
surface 
expression
10-15 Non definitive 
indication for therapy
Death rate or 
CKF: <20%
Recurrence rate: 
15%-20%
CFI Factor I Low cofactor 
level or 
activity
4-10 Remission rate: 
30%-40%
Death rate or 
CKF: 60%-70%
Recurrence rate: 
70%-90%
CFB Factor B Stabilization 
of C3b 
convertase
1-2 Remission rate: 30% Death rate and 
CKF: 79%
Remission in one 
case
C3 C3 Resistance 
to C3b 
inactivation 
5-10 Remission rate: 
40%-50%
Death rate and 
CKF: 60%
Recurrence rate: 
40%-50%
TM TM Reduction 
in C3b 
inactivation
5 Remission rate: 60% Death rate and 
CKF: 60%
Remission in one 
case
Table 2 genetic abnorMalities and clinical evolUtion of patients witH atypical HUs 
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the tissue factor with binding and activation of Factor 
VII, and formation of thrombin and fibrin polymers. 
That scenario applies particularly to the glomerular 
capillary bed, which is a fenestrated endothelium, 
whose surface of the basal membrane is rich in polya-
nions prone to Factor H1 binding, which could ex-
plain the localization of the HUS vascular injury.49,50
Membrane cofactor protein is also widely expres-
sed in the kidneys and could be found in glomeru-
lar endothelial cells by use of immunohistochemistry 
analysis.48-51 It plays an important role in the protec-
tion of glomerular endothelial cells against C3 acti-
vation, because the cofactor activity in the extract 
of those cells was completely blocked by antibodies 
anti-MCP.51 Complement factor H and MCP act in 
conjunction to control the complement activation 
in host cells. Mutation in CFH and in MCP results 
in complement activation and HUS, indicating that 
the functions of those complement regulators do not 
overlap, being both required for complement control 
and activation.
The lesion of D+ HUS cannot be distinguished 
from that of the atypical form based on histological 
analysis. It is characterized by thickening of the ca-
pillaries and arterioles, endothelial edema and deta-
ching, and accumulation of proteins and cell debris in 
the subendothelial space. Platelet thrombi occlude the 
capillary lumen. Hemolysis occurs and distorted and 
fragmented erythrocytes are evident on peripheral 
blood smears. The lesions typically affect the kidneys 
(mainly glomeruli and arterioles), but other organs 
can be involved, such as brain, heart, lungs, gastroin-
testinal tract, and pancreas.
tHroMbotic tHroMbocytopenic pUrpUra (ttp)
Immediate recognition of TTP is important, because 
the disease responds well to treatment with PE,20 but 
TTP is associated with a high mortality rate when not 
treated. In the era preceding the effective treatment 
with PE, 90% of the patients with TTP died from 
systemic microvascular thrombosis that caused myo-
cardial and cerebral infarction and kidney failure.19 
However, recognizing TTP may be difficult because 
of the variety of presentations and lack of specific 
criteria. The only consistent abnormalities are micro-
angiopathic hemolytic anemia, characterized by frag-
mentation of red blood cells, and thrombocytopenia,7 
manifestations that can also occur in other conditions.
Prior to effective therapy, the diagnosis of TTP 
was based on the progressive appearance of the “pen-
tad” of clinical manifestations: microangiopathic 
hemolytic anemia, thrombocytopenia, renal and neu-
rological abnormalities, and fever. However, the re-
cognition of the efficacy of the therapy with PE resul-
ted in the adoption of more comprehensive diagnostic 
criteria so that treatment could be initiated faster. A 
randomized study has shown the efficacy of the the-
rapy with PE only for microangiopathic hemolytic 
anemia and thrombocytopenia with no apparent al-
ternative cause; the frequency of neurological and 
renal abnormalities and fever was smaller than that 
in previous studies.20 Thrombotic thrombocytopenic 
purpura occurs primarily in adults. Children with mi-
croangiopathic hemolytic anemia, thrombocytopenia, 
and kidney failure are considered to have HUS.52,53 
That is typically preceded by abdominal pain and 
diarrhea, and has been recognized since 1983 as a 
complication of infection caused by the Stx-producing 
bacterium, E. coli O157: H7. Currently, 91% of the 
children with typical HUS survive with support care, 
without PE treatment.
Those observations have suggested that TTP and 
HUS are two distinct syndromes,1 an interpretation 
supported by studies that found a severe deficiency 
(< 5% of activity) in the vWF-cleaving protease, the 
ADAMTS13, in patients diagnosed with TTP, but 
not in patients with HUS. ADAMTS13 cleaves the 
large vWF multimers, which are synthesized and se-
creted by endothelial cells. When ADAMTS13 is not 
present, the result is an abnormal formation of large 
vWF multimers in the plasma and an increased ability 
to react with platelets and cause disseminated platelet 
thrombi, characteristic of TTP.1
However, n fact TTP and HUS are not distinct syn-
dromes, since their essential diagnostic criteria – micro-
angiopathic hemolytic anemia and thrombocytopenia 
– are the same. Neurological abnormalities are com-
monly considered as characteristic of TTP, and kidney 
failure as characteristic of HUS. Sometimes, patients 
with those syndromes have none of those abnormali-
ties or have both.59 In addition, the name of the syndro-
me – TTP or HUS – has acquired clinical importance, 
due to the suggestion that treatment with PE can be 
appropriate to TTP, but not to HUS.53 Thus, the term 
“TTP” is used to describe microangiopathic hemolytic 
anemia and thrombocytopenia occurring in adults, wi-
th no apparent alternative cause, and with or without 
associated abnormalities, conditions or causes.
Thrombotic thrombocytopenic purpura is rare in 
children; in adults, it affects mainly women, black in-
dividuals, and obeses.31
The role of measuring the activity of ADAMTS13 
and inhibitors remains uncertain.31
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The vWF multimers are produced inside megaka-
ryocytes and endothelial cells and stored in granules 
inside the platelets and in the Weibel-Palade bodies of 
endothelial cells. When compared to plasma ones, such 
large multimers bind more efficiently to the glycopro-
tein Iba component of the platelet glycoprotein Ib/IX/V 
receptor for vWF. This may be due to the fact that the 
binding site for the Iba glycoprotein in the vWF mono-
meric subunit is more exposed in large multimers than 
in small ones, which are usually circulating. The ini-
tial attack of a small amount of large vWF multimers 
against Iba glycoprotein, and subsequent formation of 
the IIb/IIIa glycoprotein complex of activated platelet 
by ADP, induces in vitro platelet aggregation in the pre-
sence of increased shear stress.22,54
Plasma vWF metalloproteinase usually prevents 
the entry of large vWF multimers in the circulation 
(or persistence). That enzyme breaks down the mul-
timers by cleaving the peptide bindings in the vWF 
monomeric subunit in position 842–843 (between 
tyrosine and methionine). The metalloproteinase is 
called ADAMTS13 (disintegrin and metalloproteina-
se with thrombospondin-1-like domain), a member 
of the family of the calcium and zinc-dependent pro-
teases. ADAMTS13 has a sequence arginine-glycine- 
aspartate, is mainly produced in hepatocytes, and its 
gene is located in chromosome 9q34.55
The large vWF multimers are probably cleaved 
by ADAMTS13 directly on the surface of endothe-
lial cells. The thrombospondin-1-like domain of 
ADAMTS13 can bind to the enzyme in the thrombos-
pondin receptor on the surface of endothelial cells.56
Severe deficiency of ADAMTS13 can be caused 
by genetic mutations (ADAMTS13: AC) or by auto-
antibodies (ADAMTS13: INH) acquired against that 
enzyme. In 1994, Tandon et al.57 reported that appro-
ximately 80% of the patients with acquired TTP had 
autoantibodies against CD36. In 2009, Davis et al.58 
showed that ADAMTS13 binds especially to CD36 
in vitro. CD36 is expressed in endothelial cells, plate-
lets, and monocytes, and binds to thrombospondin 1. 
It has not been clarified whether the autoantibodies 
block the ADAMTS13 binding to endothelial cells, 
but this is the only way of interfering with efficient 
cleavage of vWF by ADAMTS13, resulting in TTP.
diseases tHat can MiMic tHe clinical findings of ttp
Because the diagnostic criteria of TTP are not spe-
cific, multiple systemic diseases can mimic TTP, re-
sulting in misdiagnosis. The systemic diseases inclu-
de disseminated malignant neoplasias,59,60 systemic 
infections,61-63 malignant hypertension,64,69 systemic 
lupus erythematosus, and other kidney diseases.69 In 
addition, physicians should maintain continued vigi-
lance regarding the existence of possible alternative 
diseases, even after establishing the diagnosis of TTP, 
and starting treatment with PE.
treatMent of d+ HUs
Correction with isotonic saline or ringer lactate to 
prevent oliguria on the first four days, as well as 
the correction of electrolytic abnormalities by use of 
dialysis seem to play a relevant role in survival in cases 
of D+ HUS in the short run.65 The use of analgesics, 
anti-inflammatory and antimotility agents should be 
avoided; morphine and acetaminophen have good 
effects. Approximately 80% of the patients need 
blood transfusion because of symptomatic anemia. 
Platelet transfusion is indicated for important hemor-
rhages or procedures.
The use of antibiotics that interact with bacterial 
DNA, such as gyrase inhibitors (fluoroquinolones), 
alkylating agents (mytomicin C, TMP/SMX), and 
β-lactam antibiotics induce lysogenesis of the bacte-
riophage, with an increase in Stx expression. Ikeda et 
al.66 have shown that fosfomycin administered on the 
second day of diarrhea protects against the develop-
ment of HUS caused by E. coli O157:H7.
Oral administration of the first generation of the 
Gb3 analogue - Synsorb-Pk67 - when initiated after 
the diagnosis of HUS failed to improve the course of 
the disease in a randomized study.
treatMent for atypical HUs
Despite the poor prognosis of atypical HUS, after the 
introduction of the therapy with plasma, the morta-
lity rate dropped from 50% to 25%.13,68-70 However, 
the effectiveness of the use of plasma in the treatment 
of acute episodes is still controversial.71 Some studies 
have shown that a consistent percentage of patients 
with atypical HUS respond to treatment with plasma. 
Plasma exchange has been proposed to be relatively 
more effective than plasma infusion, because it should 
remove potentially toxic substances from the circula-
tion of patients.
Treatment with plasma should be initiated within 
24 hours from presentation, since its delay can incre-
ase the frequency of therapeutic failure.73
Other treatments, such as antiplatelet agents, 
prostacyclins, heparin or fibrinolytic agents, steroids, 
and immunoglobulins, have been tested, and the re-
sults have been inconsistent.13
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diagnostic and prognostic role of MeasUring 
adaMts13
Measuring ADAMTS13 may not guarantee initial 
diagnosis and therapeutic decision, but it is important 
for the prognosis. Even if most patients with severe 
ADAMTS13 deficiency do not have kidney failu-
re, measuring its activity can distinguish TTP from 
HUS.74 Some patients with severe ADAMTS13 defi-
ciency can have acute kidney failure. An ADAMTS13 
activity < 5% seems to be specific for TTP, but it does 
not identify all patients who can relapse; ADAMTS13 
activity < 10% essentially identifies all patients at risk 
for relapsing, but it is not specific for that purpose; 
patients with sepsis75,76 and liver cirrhosis77 can also 
have ADAMTS13 activity < 10%.
treatMent witH “plasMa excHange”
Plasma exchange is the essential treatment for all pa-
tients diagnosed as having TTP, with or without kid-
ney failure,20,78 but the number of PE sessions required 
for remission is extremely variable. Before effective 
treatment, most survivors were children,19 which can 
reflect their inherent resistance to thrombosis, as 
suggested by observations that venous and arterial 
thromboses are rare in children.79
The hypothesis that tries to explain the efficacy of 
PE treatment considers that ADAMTS13 deficiency 
is corrected by the infusion of plasma and inhibitor; 
autoantibodies are removed by use of apheresis, re-
sulting in recovery of ADAMTS13 activity.1 However, 
most adult patients diagnosed with TTP do not have 
severe ADAMTS13 deficiency, and many seem to also 
respond to PE, like those presenting with bloody diar-
rhea or who have TTP induced by quinine.80-81 The 
mechanism of the possible efficiency of the PE treat-
ment in those patients is unknown.
Even if several cases have suggested that plasma 
cryosupernatant, which is deficient in vWF, can be 
better than fresh plasma as a reposition product in 
PE, a small randomized clinical trial failed in the at-
tempt to confirm that finding.81
Based on those observations, PE should be per-
formed every day and maintained until platelet count 
returns to normal.31,82 Levels of LDH, which reflect 
tissue ischemia and hemolysis,83 are also markers of 
response to treatment.29
coMplications of tHe treatMent witH “plasMa excHange”
When deciding about initiating PE treatment, the po-
tential complications and confidence in TTP diagno-
sis should be taken into account. Of 206 consecutive 
patients assessed over a period of nine years in the 
registry of Oklahoma, 57 (28%) had complications 
and the death of five (2.4%) was attributed to that 
therapeutic approach. 84-86 The deaths were caused 
by hemorrhage or pneumothorax, complicating the 
insertion of central venous catheter (two patients), 
or sepsis attributed to central venous catheter (three 
patients). Two other patients had cardiac arrest with 
pulse electrical activity: one caused by anaphylactic 
reaction to plasma and the other caused by cardiac 
tamponade related to catheter insertion.
adjUvant treatMent
There is evidence that the PE treatment would have only 
a transient effect on the presumably autoimmune basis 
of the disease, and that additional immunosuppressive 
treatment could lead to a longer-lasting response.31
Treatment with immunosuppressive agents is re-
served for patients suspected of having ADAMTS13 
autoimmune deficiency. Corticoids are the immunosu-
ppressive agents initially administered. Others agents, 
such as rituximab87 and cyclosporine,88 are used for 
more critically-ill patients. Aspirin is not used as ad-
juvant treatment, but is appropriate for patients with 
standard cardiologic or neurological indication and 
without severe thrombocytopenia.
Mortality
Despite the institution of treatment considered opti-
mal, mortality among patients with TTP remains ap-
proximately 15%. However, 50% of the deaths can 
be attributed to complications from the treatment 
with PE or hospitalization, such as sepsis, hemorrha-
ge, and thrombosis.89
treatMent of tHe patients wHo acHieved reMission
In patients with severe ADAMTS13 deficiency, the 
risk of relapse is approximately 40%, but it is rare in 
patients with less severe deficiency; 50% of these pa-
tients can relapse, most within one year.89 The value 
of maintaining the immunosuppressive treatment or 
of measuring ADAMTS13 activity during remission 
is unknown. Patients can have severe ADAMTS13 
deficiency for many years with no clinical evidence of 
TTP. In continuing with treatment, it is paramount to 
to insist with the patient to immediately have a plate-
let count, when any acute symptom occurs.
Because many young women develop TTP associa-
ted with pregnancy,90,91 the risk of relapse with a futu-
re pregnancy becomes a concern. Follow-up study of 
30 pregnancies in 19 women who had TTP revealed 
that most subsequent pregnancies were not affected.91
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long-terM oUtcoMe
Even if relapse is a major problem, it is not the only 
one. After recognizing the disease, patients have a 
significantly altered quality of life, with progressive 
memory loss and fatigue.92
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